Nanoparticle-Directed Photothermal Ablation of Primary Brain Tumors guided by Mag

Mag 引导的纳米粒子定向光热消融原发性脑肿瘤

• 批准号: 8260230
• 负责人: R JASON STAFFORD
• 金额: $ 47.92万
• 依托单位: NANOSPECTRA BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-12 至 2014-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8260230
• 关键词: Ablation; Acute; Adverse effects; Animals; Area; Brain; Brain Neoplasms; Breeding; Cancer Center; Cancer Patient; Canis familiaris; Cells; Childhood; Chronic; Clinical Protocols; Clinical Trials; Comorbidity; Conflict (Psychology); Contralateral; Cultured Cells; Diffusion; Disorder by Site; Engraftment; Evaluation; Feasibility Studies; Fiber; Glioma; Gold; Growth; Headache; Histopathology; Hour; Human; Image; Imaging technology; Immunosuppression; In Vitro; Incidence; Infusion procedures; Intracranial Pressure; Lasers; Lead; Lesion; Long-Term Effects; Magnetic Resonance; Magnetic Resonance Imaging; Malignant Neoplasms; Maps; Measures; Modality; Modeling; Monitor; Morbidity - disease rate; Nature; Neoplasm Metastasis; Operative Surgical Procedures; Optics; Outcome; Pathology; Patients; Positioning Attribute; Primary Brain Neoplasms; Primary Neoplasm; Process; Quality of life; Radiation therapy; Radiosurgery; Recurrence; Research Project Grants; Sampling; Second Primary Neoplasms; Seizures; Shapes; Skull Base Neoplasms; Solid Neoplasm; Source; Specificity; System; Techniques; Technology; Temperature; Time; Tissues; Translating; Treatment Protocols; Tumor Volume; Ultrasonography; Work; base; brain tissue; cancer therapy; chemotherapy; clinical application; cranium; cryogenics; cytotoxicity; dosimetry; glioma cell line; image guided therapy; improved; in vivo; irradiation; microwave electromagnetic radiation; minimally invasive; nanoparticle; novel; particle; public health relevance; radiofrequency; relating to nervous system; response; success; treatment duration; treatment planning; tumor; uptake

DESCRIPTION (provided by applicant): The incidence of brain tumors in the U.S., including primary and metastases of other cancers, is estimated to be around 200,000 per year. Current treatments consist of open surgery, radiation, and chemotherapy, but these treatments are by no means curative for most patients and result in substantial side effects for some patients. There is a significant need for therapies that improve outcomes with fewer side effects than current therapies, but which are also synergistic with current approaches. We have previously completed a feasibility study of a minimally invasive, nanoparticle-directed, image- guided therapy for the photothermal ablation of solid tumors in a canine brain tumor model. This proposed research project will translate these preliminary studies into a clinical application and provide the basis for a human clinical trial at the conclusion of the project. Using a canine glioma cell line, we will demonstrate that systemically-delivered, infrared absorbing nanoparticles will self-select for the tumor boundary. Using Magnetic Resonance temperature imaging, we will demonstrate that the photothermal ablation can be confined to a tumor-specific treatment zone, resulting in clear margins with minimal damage to adjacent neural tissue. The selectivity of this therapy will be assessed by acute (48-72 hour) pathology and longer (6 week) survival studies. The minimally-invasive nature of the percutaneous photothermal treatment should lead to an enhancement of patients' quality of life as a result of reduced tumor volume and reduced intracranial pressure, which should reduce the incidence of seizures and headaches. And, a lowered morbidity in cancer patients would permit other treatments such as chemotherapy which do not conflict with this photothermal therapy. Additionally, a minimally invasive, percutaneously delivered photothermal therapy may permit treatment of non-resectable deeper or skull-based tumors. PUBLIC HEALTH RELEVANCE: The incidence of brain tumors in the U.S., including primary and metastases of other cancers, is approximately 200,000 per year. The currently accepted treatment modalities for tumors of the brain include surgery, whole-brain radiotherapy, stereotactic radiosurgery, chemotherapy; or some combination of these, but these treatments are by no means curative for most patients and result in substantial side effects for some patients. We will develop a minimally invasive therapy to eliminate or reduce in size primary tumors in the brain and skull, improving outcomes and reducing morbidity.

描述（由申请人提供）：在美国，脑肿瘤（包括原发性癌症和其他癌症的转移瘤）的发病率估计每年约为 200,000 例。目前的治疗方法包括开放手术、放疗和化疗，但这些治疗对大多数患者来说根本无法治愈，并且会给一些患者带来严重的副作用。非常需要能够改善结果且副作用比当前疗法更少，但也与当前方法具有协同作用的疗法。我们之前已经完成了一项微创、纳米颗粒导向、图像引导疗法的可行性研究，用于犬脑肿瘤模型中实体瘤的光热消融。该拟议的研究项目将把这些初步研究转化为临床应用，并为项目结束时的人体临床试验提供基础。使用犬神经胶质瘤细胞系，我们将证明全身递送的红外吸收纳米粒子将自我选择肿瘤边界。使用磁共振温度成像，我们将证明光热消融可以限制在肿瘤特异性治疗区域，从而产生清晰的边缘，同时对邻近神经组织的损伤最小。该疗法的选择性将通过急性（48-72 小时）病理学和较长（6 周）生存研究来评估。经皮光热治疗的微创性质应会因肿瘤体积减小和颅内压降低而提高患者的生活质量，从而减少癫痫和头痛的发生率。而且，癌症患者发病率的降低将允许其他治疗，例如与这种光热疗法不冲突的化疗。此外，微创、经皮递送的光热疗法可以治疗不可切除的更深部或颅骨肿瘤。 公共卫生相关性：在美国，脑肿瘤（包括其他癌症的原发性肿瘤和转移性肿瘤）的发病率每年约为 200,000 例。目前公认的脑肿瘤治疗方式包括手术、全脑放疗、立体定向放射外科、化疗；或这些治疗的某种组合，但这些治疗对于大多数患者来说根本无法治愈，并且会给某些患者带来严重的副作用。我们将开发一种微创疗法来消除或缩小大脑和颅骨中的原发性肿瘤，从而改善结果并降低发病率。